• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

恩格列净相关性胰腺炎：对钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的考量

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors.

作者信息

Dziadkowiec Karolina N, Stawinski Peter M, Proenza Jose

机构信息

The University of Miami, JFK Regional Campus, Division of Internal Medicine, Lake Worth, FL.

West Palm Beach VA Medical Center, Division of Gastroenterology and Hepatology, West Palm Beach, FL.

出版信息

ACG Case Rep J. 2021 Jan 19;8(1):e00530. doi: 10.14309/crj.0000000000000530. eCollection 2021 Jan.

DOI:10.14309/crj.0000000000000530
PMID:33490300
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7813547/
Abstract

Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tract infections among others. We present a case of severe epigastric abdominal pain consistent with acute pancreatitis in the setting of empagliflozin use, suggesting a possible drug-induced acute pancreatitis.

摘要

恩格列净属于钠-葡萄糖协同转运蛋白2抑制剂类药物，2014年被美国食品药品监督管理局批准用于治疗2型糖尿病。该药物常见的副作用包括症状性低血压、低血糖和尿路感染等。我们报告一例在使用恩格列净过程中出现与急性胰腺炎相符的严重上腹部疼痛的病例，提示可能为药物性急性胰腺炎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1da8/7813547/ad5afea005b2/ac9-8-e00530-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1da8/7813547/ad5afea005b2/ac9-8-e00530-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1da8/7813547/ad5afea005b2/ac9-8-e00530-g001.jpg

相似文献

1
Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors.恩格列净相关性胰腺炎：对钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的考量
ACG Case Rep J. 2021 Jan 19;8(1):e00530. doi: 10.14309/crj.0000000000000530. eCollection 2021 Jan.
2
Adverse Side Effects: Empagliflozin-Related Acute Pancreatitis Case Report.不良反应：恩格列净相关急性胰腺炎病例报告。
Cureus. 2020 Dec 27;12(12):e12325. doi: 10.7759/cureus.12325.
3
Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin.恩格列净起始治疗两周后一名57岁女性发生胰腺炎
AACE Clin Case Rep. 2023 Apr 13;9(4):104-107. doi: 10.1016/j.aace.2023.04.005. eCollection 2023 Jul-Aug.
4
The role of empagliflozin in the management of type 2 diabetes by patient profile.恩格列净在根据患者情况管理2型糖尿病中的作用。
Ther Clin Risk Manag. 2015 May 5;11:739-49. doi: 10.2147/TCRM.S71762. eCollection 2015.
5
Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.恩格列净治疗 2 型糖尿病：基于 3 期临床试验的安全性和疗效概述。
J Diabetes. 2015 Jul;7(4):448-61. doi: 10.1111/1753-0407.12278. Epub 2015 May 18.
6
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：一类不断发展的抗糖尿病药物。
Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014.
7
A Rare Case of Sodium-Glucose Cotransporter-2 Inhibitor-Induced Acute Pancreatitis.1例罕见的钠-葡萄糖协同转运蛋白2抑制剂所致急性胰腺炎
Cureus. 2023 Nov 24;15(11):e49369. doi: 10.7759/cureus.49369. eCollection 2023 Nov.
8
Empagliflozin in type 1 diabetes.恩格列净用于1型糖尿病治疗
Diabetes Metab Syndr Obes. 2019 Aug 22;12:1555-1561. doi: 10.2147/DMSO.S194688. eCollection 2019.
9
A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus.恩格列净全面综述：用于治疗2型糖尿病的最具特异性和强效的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂。
Diabetes Metab Syndr. 2019 May-Jun;13(3):2001-2008. doi: 10.1016/j.dsx.2019.04.035. Epub 2019 Apr 26.
10
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.钠-葡萄糖协同转运蛋白2抑制剂在糖尿病治疗中的应用：心血管和肾脏效应、潜在机制及临床应用
Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28.

引用本文的文献

1
SGLT2 inhibitor use in the management of feline diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂在猫糖尿病管理中的应用
J Vet Pharmacol Ther. 2025 Jan;48 Suppl 1(Suppl 1):19-30. doi: 10.1111/jvp.13466. Epub 2024 Jul 2.
2
A Rare Case of Sodium-Glucose Cotransporter-2 Inhibitor-Induced Acute Pancreatitis.1例罕见的钠-葡萄糖协同转运蛋白2抑制剂所致急性胰腺炎
Cureus. 2023 Nov 24;15(11):e49369. doi: 10.7759/cureus.49369. eCollection 2023 Nov.
3
Pancreatitis in a 57-Year-Old Female Two Weeks After Initiation of Empagliflozin.恩格列净起始治疗两周后一名57岁女性发生胰腺炎

本文引用的文献

1
Drug-Induced Acute Pancreatitis in Adults: An Update.成人药物性急性胰腺炎：最新进展
Pancreas. 2019 Nov/Dec;48(10):1263-1273. doi: 10.1097/MPA.0000000000001428.
2
Genetics, Cell Biology, and Pathophysiology of Pancreatitis.胰腺炎的遗传学、细胞生物学和病理生理学。
Gastroenterology. 2019 May;156(7):1951-1968.e1. doi: 10.1053/j.gastro.2018.11.081. Epub 2019 Jan 18.
3
Empagliflozin-Induced Pancreatitis.恩格列净所致胰腺炎。
AACE Clin Case Rep. 2023 Apr 13;9(4):104-107. doi: 10.1016/j.aace.2023.04.005. eCollection 2023 Jul-Aug.
4
SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.SGLT2 抑制剂相关胰腺炎：通过自发报告的不匀称性分析和病例报告回顾识别信号。
Int J Clin Pharm. 2022 Dec;44(6):1425-1433. doi: 10.1007/s11096-022-01476-7. Epub 2022 Oct 12.
5
Empagliflozin induces apoptotic-signaling pathway in embryonic vasculature: and approaches chick's yolk sac membrane model.恩格列净诱导胚胎血管中的凋亡信号通路：并采用鸡卵黄囊膜模型。
Front Pharmacol. 2022 Sep 1;13:970402. doi: 10.3389/fphar.2022.970402. eCollection 2022.
6
Empagliflozin-Induced Pancreatitis: A Case Report Pattern.恩格列净诱发的胰腺炎：一例报告模式
Cureus. 2022 May 21;14(5):e25189. doi: 10.7759/cureus.25189. eCollection 2022 May.
7
Probable Dapagliflozin-Associated Acute Pancreatitis.可能与达格列净相关的急性胰腺炎
Diabetes Spectr. 2022 Spring;35(2):232-238. doi: 10.2337/ds21-0025. Epub 2021 Sep 28.
Ann Pharmacother. 2018 Nov;52(11):1158-1159. doi: 10.1177/1060028018786716. Epub 2018 Jul 2.
4
Drug-Induced Necrotizing Pancreatitis With a Focus on Canagliflozin.
Am J Ther. 2017 Jul/Aug;24(4):e496. doi: 10.1097/MJT.0000000000000561.
5
Acute Pancreatitis.急性胰腺炎
N Engl J Med. 2017 Feb 9;376(6):598-9. doi: 10.1056/NEJMc1616177.
6
Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus.卡格列净使用中出现的急性胰腺炎：2型糖尿病新型治疗方法的一种罕见副作用。
J Basic Clin Pharm. 2015 Jun;6(3):101-2. doi: 10.4103/0976-0105.160753.
7
Canagliflozin-induced pancreatitis: a rare side effect of a new drug.卡格列净诱发的胰腺炎：一种新药的罕见副作用。
Ther Clin Risk Manag. 2015 Jun 26;11:991-4. doi: 10.2147/TCRM.S86641. eCollection 2015.
8
Canagliflozin-Associated Acute Pancreatitis.卡格列净相关的急性胰腺炎
Am J Ther. 2016 May-Jun;23(3):e972-3. doi: 10.1097/MJT.0000000000000135.
9
Canagliflozin: Improving diabetes by making urine sweet.卡格列净：使尿液变甜，改善糖尿病。
Cleve Clin J Med. 2013 Nov;80(11):683-7. doi: 10.3949/ccjm.80a.13053.
10
Drug-induced acute pancreatitis: an evidence-based review.药物性急性胰腺炎：一项基于证据的综述。
Clin Gastroenterol Hepatol. 2007 Jun;5(6):648-61; quiz 644. doi: 10.1016/j.cgh.2006.11.023. Epub 2007 Mar 28.